Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-3000 in treatment-resistant depression
NCT06965569Phase 1Completed
- Sponsor
- Alar Pharmaceuticals Inc.
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALA-3000 in treatment-resistant depression (TRD) (4 cohorts), sponsored by Alar Pharmaceuticals Inc. Primary endpoints: Adverse Events at 36 days, Orthostatic Blood Pressure at 36 days and 17 more. Started Apr 2025; status: completed.
02
Drugs
ALA-3000
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06965569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965569.